中药联合化疗治疗广泛期小细胞肺癌临床研究

目的:探讨中药喜丹汤联合化疗治疗广泛期小细胞肺癌能否提高疗效。方法:经病理明确诊断的未经手术治疗的120例广泛期小细胞肺癌患者,随机分为对照组与研究组各60例,对照组采用EP方案化疗治疗,研究组采用中药喜丹汤联合EP方案治疗。结果:研究组与对照组总有效率(CR+PR)分别为75.0%(45/60)、56.7%(33/60),两组比较有统计学差异(P<0.05),中位生存时间及生存时间曲线:研究组10.9个月(10.5¹1.2);对照组8.1个月(7.411.2);对照组8.1个月(7.4⁸.8),两组比较有显著的统计学意义(P<0.001);1年生存率研究组为53.3%(32/60),对照组为31.7%(19/60),两组比较差异有统计学意义(P<0.05);常见的毒副反应主要表现为血液学毒性及胃肠道反应,患者均可耐受。结论:中药联合化疗能提高广泛期小细胞肺癌的疗效,延长其生存期。

Clinical research of traditional Chinese medicine combined with chemo-therapy in treating extensive stage small cell lung cancer

Objective: To investigate the clinic effect of traditional Chinese medicine combined with chemotherapy in treating extensive stage small cell lung cancer( ES-SCLC). Methods: 120 cases of patients with ES-SCLC treated without surgery were divided randomly into the control group treated with EP regimen and the experimental group treated with traditional Chinese medicine( XIDAN soup) combined with EP regimen,with sixty patients in each group. Results: In the study group the overall response rate( CR + PR) was75. 0%,In the control group the overall response rate( CR + PR) was 56. 7%. There was statistical difference in the overall response rate between the two groups( P < 0. 05). The median survivals and time-survivor curve for the control group and study group were 8. 1months and 10. 9 months respectively,which was statistically different between the two groups( P < 0. 05). 1 year survival rate for the control group and study group were 53. 3% and 31. 7%,respectively,which was statistically different between the two groups( P <0. 05). The major side effects were hematologic toxicities and gastrointestinal reactions,and the patients can tolerate it. Conclusion: The treatment of Chinese medicine combined with chemotherapy can improve the therapeutic efficacy and prolong survival period of ESSCLC patients.